



STAY CURRENT with FDA-Approved Immunotherapy Treatments

Free for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

All healthcare professionals in the clinical setting, students, patients and patient advocates attend for FREE! For full accreditation information or to register for Nashville's upcoming ACI, please visit sitcancer.org/aci/nashville

NASHVILLE ACI Program Information

Wednesday, Dec. 4, 2019
3:30 – 8:20 p.m. CST

Holiday Inn Express Nashville Downtown Conference Center
920 Broadway
Nashville, TN 37203

Organizers:
Suzanne Jones, PharmD – *Sarah Cannon*
Jeffrey C. Rathmell, PhD – *Vanderbilt University School of Medicine*
Anil Shanker, PhD – *Meharry Medical College School of Medicine*

Register yourself and invite a colleague to ensure your team is up to date on the latest FDA-approved immunotherapy treatments

To register, please visit:

sitcancer.org/aci/nashville

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



Postgraduate Institute
for Medicine



Society for Immunotherapy of Cancer



AMERICAN ACADEMY OF
EMERGENCY MEDICINE
CHAMPION OF THE EMERGENCY PHYSICIAN



Association of Community Cancer Centers



Hematology/Oncology
Pharmacy Association

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.